A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

Hamza Hasan, Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan, Ana P. Kiess, Shirl Dipasquale, James Huang, Terry Caldwell, Jessica Leitzel, Danielle Wendler, Hao Wang, Elizabeth Thompson, Jonathan Powell, Sara Dudley, Curtiland Deville, Stephen C. Greco, Daniel Y. Song, Theodore L. DeweeseMichael A. Gorin, Steven P. Rowe, Sam Denmeade, Mark Markowski, Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Channing J. Paller, Phuoc T. Tran

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science